April 9, 2019

Zogenix Receives Refusal to File Letter from FDA for FINTEPLA® New Drug Application

Zogenix, Inc. (ZGNX) announced April 8 that it received a Refusal to File (RTF) letter from the FDA regarding its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine hydrochloride) for the treatment of seizures associated with Dravet syndrome.

Upon its preliminary review, the FDA determined that the NDA, submitted on February 5, 2019, was not sufficiently complete to permit a substantive review.  In the letter, the FDA cited two reasons for the RTF decision: first, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA. The FDA has not requested or recommended additional clinical efficacy or safety studies.

Related News